Ruxolitinib Versus Best Available Therapy in Patients With Glucocorticoid-Refractory Chronic Graft-Vs-Host Disease: Primary Findings From the Phase 3, Randomized REACH3 Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [21] REACH-3 trial design: A Phase 3, Randomized Study to Assess Ruxolitinib over BAT in Patients with Corticosteroid-Refractory Chronic Graft-versus-Host Disease Post Allo-HSCT
    Zeiser, Robert
    Ram, Ron
    Foley, Stephen Ronan
    Yeshurun, Moshe
    Locatelli, Franco
    Gadbaw, Brian
    Atienza, Edric
    Hollaender, Norbert
    Teshima, Takanori
    BONE MARROW TRANSPLANTATION, 2018, 53 : 444 - 446
  • [22] Reach-2 Trial Design: A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Compared to Best Available Therapy in Patients with Corticosteroid-Refractory Acute Graft vs Host Disease after Allogeneic Stem Cell Transplantation
    Socie, Gerard
    Niederwieser, Dietger
    von Bubnoff, Nikolas
    Szer, Jeff
    Mohty, Mohamad
    Laughlin, Mary
    Molloy, Betty
    O'Sullivan-Djentuh, Leslie
    Zeiser, Robert
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S203 - S203
  • [23] Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study
    Socie, Gerard
    Xue, Zhenyi
    Bhatt, Valkal
    Galvin, John
    Mohty, Mohamad
    BLOOD, 2022, 140 : 4765 - 4766
  • [24] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    Harrison, C. N.
    Vannucchi, A. M.
    Kiladjian, J-J
    Al-Ali, H. K.
    Gisslinger, H.
    Knoops, L.
    Cervantes, F.
    Jones, M. M.
    Sun, K.
    McQuitty, M.
    Stalbovskaya, V.
    Gopalakrishna, P.
    Barbui, T.
    LEUKEMIA, 2016, 30 (08) : 1701 - 1707
  • [25] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    C N Harrison
    A M Vannucchi
    J-J Kiladjian
    H K Al-Ali
    H Gisslinger
    L Knoops
    F Cervantes
    M M Jones
    K Sun
    M McQuitty
    V Stalbovskaya
    P Gopalakrishna
    T Barbui
    Leukemia, 2016, 30 : 1701 - 1707
  • [26] Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease: Results from the Phase 2 REACH1 Trial
    Jagasia, Madan
    Ali, Haris
    Schroeder, Mark A.
    Shah, Nirav N.
    Chen, Yi-Bin
    Dawkins, Fitzroy
    Arbushites, Michael
    Tian, Chuan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [27] Ruxolitinib in Pediatric Patients with Treatment-Naive or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study
    Locatelli, Franco
    Kang, Hyoung Jin
    Bruno, Benedicte
    Gandemer, Virginie
    Rialland, Fanny
    Faraci, Maura
    Takahashi, Yoshiyuki
    Koh, Katsuyoshi
    Bittencourt, Henrique
    Cleary, Grace
    Rosko, Christine
    Roussou, Pantelia
    St Pierre, Annie
    Prahallad, Anirudh
    Diaz-de-Heredia, Cristina
    BLOOD, 2022, 140 : 1376 - 1378
  • [28] Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease
    Jagasia, Madan
    Perales, Miguel-Angel
    Schroeder, Mark A.
    Ali, Haris
    Shah, Nirav N.
    Chen, Yi-Bin
    Arbushites, Michael C.
    Dawkins, Fitzroy
    Tian, Chuan
    Khoury, Hanna Jean
    BLOOD, 2018, 132
  • [29] Results From REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (03) : 3 - 5
  • [30] Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    C N Harrison
    A M Vannucchi
    J-J Kiladjian
    H K Al-Ali
    H Gisslinger
    L Knoops
    F Cervantes
    M M Jones
    K Sun
    M McQuitty
    V Stalbovskaya
    P Gopalakrishna
    T Barbui
    Leukemia, 2017, 31 : 775 - 775
12345